My research activities are concentrated on cancer screening and early diagnosis. There is potential for considerable saving of lives from cancer if it were diagnosed at an earlier stage.
Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet (2017) 389:1299-1311. PMID: 28236467
Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. Lancet Oncol (2016) 17(1):109-14. PMID: 26655422
Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single arm FH01 study. Lancet Oncol (2010) 11: 1127-34. PMID: 21093374
Swedish Two-County Trial: impact of mammographic screening on breast cancer mortality during three decades. Radiol (2011) 260: 658-63. PMID: 21712474
2019-2023- NIHR, Policy Research Unit in Cancer Awareness, Screening and Early Diagnosis, £5M
Beneficial effect of consecutive screening mammography examinations on mortality from breast cancer: A prospective study Duffy SW, Tabár L, Yen AMF et al. Radiology (2021) 299(7) 541-547
Targeted encouragement of GP consultations for possible cancer symptoms: a randomised controlled trial Laake JP, Vulkan D, Quaife SL et al. British Journal of General Practice (2021) 71(7) E39-E346
The Barts Health NHS Trust COVID-19 cohort: characteristics, outcomes and risk scoring of patients in East London Zenner D International Journal of Tuberculosis and Lung Disease (2021) (1)
Patient barriers and facilitators of colonoscopy use: A rapid systematic review and thematic synthesis of the qualitative literature. Kerrison RS, Sheik-Mohamud D, McBride E et al. Prev Med (2021) 145(2) 106413
Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative. Giorgi Rossi P, Lebeau A, Canelo-Aybar C et al. Br J Cancer (2021) 124(2) 1503-1512
Colorectal cancer risk following polypectomy in a multicentre, retrospective, cohort study: an evaluation of the 2020 UK post-polypectomy surveillance guidelines. Cross AJ, Robbins EC, Pack K et al. Gut (2021) (2)
Artificial intelligence techniques that may be applied to primary care data to facilitate earlier diagnosis of cancer: Systematic review Jones OT, Calanzani N, Saji S et al. Journal of Medical Internet Research (2021) 23(7)
Calibration of the LLP Lung Cancer Risk Stratification Model: Prospective Validation in the UKLS Cohort of 76,000 People Field J, Vulkan D, Davies M et al. JOURNAL OF THORACIC ONCOLOGY (2021) 16(11) S212-S212
Including a general practice endorsement letter with the testing kit in the Bowel Cancer Screening Programme: Results of a cluster randomised trial. Cross AJ, Myles J, Greliak P et al. J Med Screen (2021) (2) 969141321997480
Benefits and harms of breast cancer mammography screening for women at average risk of breast cancer: A systematic review for the European Commission Initiative on Breast Cancer. Canelo-Aybar C, Ferreira DS, Ballesteros M et al. J Med Screen (2021) (2) 969141321993866
Oleg Blyuss, Amanda Dibden, Roberta Maroni, Daniel Vulkan
Senior Data Manager
I am a statistician by training, educated at the University of Edinburgh and Imperial College, London. I have worked in the UK, Singapore, France, Sweden and Russia.
For the last three decades, my research has been mainly in cancer epidemiology, prevention and screening. I worked on the pioneering Swedish Two-County Trial of breast cancer screening, on which the UK's national breast screening programme was based.
Since then I have taken a major role in a number of other trials of cancer screening, in breast, colorectal and lung cancer. These include the UK Trial of Flexible Sigmoidoscopy whose results changed national policy within weeks of publication, and the FH01 study of annual mammography in young women at enhanced familial risk of breast cancer, which contributed to the NICE guidelines on breast cancer risk management.
I am currently Director of the Policy Research Unit in Cancer Awareness, Screening and Early Diagnosis, funded by the Department of Health.
It is a collaboration between researchers from seven institutions (Queen Mary University of London, UCL, King's College London, London School of Hygiene and Tropical Medicine, Hull York Medical School, Durham University and Peninsula Medical School). The aim of the unit is to carry out research to inform policy to promote earlier diagnosis of cancer, symptomatically or by screening, and as a consequence bring down mortality from cancer.
In our strand of the Unit in Queen Mary University of London, our team concentrates on research aimed at evaluating cancer screening programmes, and devising innovations to these which will improve their effect on death from cancer, enhance their acceptability to the public and minimise side effects of screening, such as false positive rates.